The Radiological Society of North America (RSNA) and diagnostic imaging certification firm RadSite have teamed on a new initiative called the RSNA Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging.
QIBA Profile provides qualitative and quantitative data for single- and multi-time point comparative assessments of oncology therapy, the organizations said.
RadSite will help RSNA launch QIBA Profile in the U.S. A similar test trial was recently completed in Europe, the two organizations said.
The profile is intended to support the use of imaging biomarkers in clinical trials and practice as well as to characterize and reduce standardized uptake value variability, according to the RSNA and RadSite.
